AGP Picks
View all

Cloud-Clone Launches Allergy Research Portfolio Ahead of Peak Rhinitis Season

News originally published by

EIN Presswire

Integrated toolbox supports pre-clinical research for type-2 airway inflammatory disorders

HUSTON, TX, UNITED STATES, November 17, 2026 /EINPresswire.com/ -- Seasonal transitions bring recurring bouts of sneezing, nasal congestion and watery eyes for countless individuals worldwide, symptoms frequently misattributed to the common cold yet often stemming from allergic rhinitis. Closely linked to asthma, allergic rhinitis represents a major type-2 hypersensitivity disorder. Published research has mapped a well-defined molecular cascade driven by IgE, Th2-associated cytokines and epithelial-derived alarmins. Reliable biological reagents and disease-recapitulating animal models are essential to dissect these complex immune events. Cloud-Clone Corp. offers a comprehensive portfolio of reagents and pre-clinical services to advance allergic airway-disease investigation.
Figure Seasonal-Triggered Allergic Rhinitis
Each fall and winter, cold dry air, indoor dust mites, pollen and particulate matter combine to trigger allergic rhinitis episodes. Allergic rhinitis and bronchial asthma follow the “one airway, one disease” paradigm. Poorly controlled rhinitis exacerbates lower-airway inflammation, linking nasal mucosal responses to bronchial hyperreactivity through IgE-mediated type-I hypersensitivity.
The pathological cascade of allergic airway disease operates across four key tiers. First, IgE acts as the master switch for type-I hypersensitivity. Upon antigen exposure, Th2-cell-secreted IL-4 drives B-cell class-switch recombination to generate antigen-specific IgE. IgE binds FcεRI receptors on mast cells and basophils to establish sensitization. Re-exposure to allergen triggers mast-cell degranulation and release of histamine and other mediators, producing sneezing, nasal pruritus and rhinorrhea. Serum total and allergen-specific IgE serve as gold-standard biomarkers for sensitization status.
Second, Th2-derived cytokines amplify inflammatory responses. IL-4 sustains Th2 polarization and IgE synthesis; IL-5 recruits and prolongs eosinophil survival; IL-13 drives mucus hypersecretion and airway remodeling. Conversely, Th1-secreted IFN-γ counterbalances Th2-dominant inflammation. The IFN-γ-to-IL-4 ratio is widely applied to quantify Th1/Th2 immune imbalance.
Third, epithelial-origin alarmins function as upstream sentinel triggers. Allergens and pollutants damage airway epithelium, inducing secretion of TSLP, IL-33 and IL-25. These alarmins polarize dendritic cells toward Th2 phenotypes and activate group-2 innate lymphoid cells (ILC2), igniting type-2 inflammation prior to adaptive-immune engagement. TSLP has become a high-priority therapeutic target for allergic-disease drug development.
Fourth, extended biomarkers enrich the analytical panel: IL-31 mediates allergic pruritus; IL-17 and IL-25 participate in neutrophilic or mixed airway inflammation; IL-10 reflects regulatory immune homeostasis. Every node in this signalling network requires robust quantitative laboratory tools.
Animal models bridge purely in-vitro molecular observations and organism-level phenotypes such as sneezing, nasal scratching and airway hyperresponsiveness. The widely-adopted ovalbumin (OVA) sensitization-and-challenge system recapitulates key features of human allergic airway disease. During sensitization, intraperitoneal injection of OVA mixed with aluminium hydroxide adjuvant induces allergen-specific IgE production. Subsequent intranasal or aerosol OVA challenge elicits immediate hypersensitivity reactions. Allergic-rhinitis-model readouts include behavioural scoring (sneezing, nasal scratching), histopathological assessment of nasal-tissue injury and eosinophilic infiltration, alongside serum biomarkers such as IgE, IL-4 and IFN-γ. Rats are convenient for intranasal-challenge operations, while BALB/c mice are preferred for genetic and mechanistic studies. Cloud-Clone provides established asthma-model services alongside custom modelling for allergic rhinitis and allergic dermatitis, paired with histopathology and multi-time-point tissue collection to generate publication-grade datasets.
Cloud-Clone’s complete toolset for allergy research covers six interconnected modules, compatible with human, mouse, rat, rabbit and guinea-pig biological samples:
1.ELISA Kits: Quantitative readouts for IgE, Th2 cytokines (IL-4, IL-5, IL-13), alarmins (TSLP, IL-33, IL-25), plus IFN-γ, IL-31, IL-17 and IL-10. Assays support serum, plasma, tissue homogenate and bronchoalveolar-lavage-fluid specimens.
2.Multiplex Assays (Luminex / CBA platforms): Simultaneous quantification of multiple cytokines from limited sample volumes, well-suited for longitudinal animal studies and high-throughput drug screening.
3.Recombinant Proteins: Bioactive proteins including IL-4, IL-33 and TSLP for *in-vitro cellular stimulation, pathway investigation and assay-standard preparation; custom protein production is available for non-stock targets.
4.Target-Specific Antibodies: Monoclonal and polyclonal antibodies validated for western blot, immunohistochemistry and immunofluorescence, enabling visualization of inflammatory-cell infiltration and alarmin expression in respiratory tissues. Custom antibody generation and fluorophore-/enzyme-labelling services are also offered.
5.Animal-Model & In-Vivo Services: SPF-facility-supported pre-clinical modelling for respiratory allergic disorders, customizable study endpoints, group design and pathological evaluation.
6.Contract Testing Services: Outsourced biochemical and cellular assays with standardized workflows and full experimental reports for laboratories with limited in-house detection capacity.
Reagents, proteins, antibodies and animal-model services follow unified quality-control standards. Assay antibodies and recombinant proteins are produced in-house, minimizing inter-batch inconsistency frequently encountered when combining supplies from multiple vendors.
A typical pre-clinical anti-allergic-rhinitis drug-evaluation workflow demonstrates how these resources work together. Investigators may commission Cloud-Clone to establish an OVA-sensitized allergic-rhinitis model. Baseline behavioural scoring of sneezing and nasal scratching confirms model establishment. Serum IgE, IL-4 and IFN-γ are quantified by ELISA or multiplex panels to verify Th2-skewed sensitization. Post-intervention measurement of TSLP, IL-33, IL-25, IL-5 and IL-13 distinguishes whether candidate compounds act on alarmin signalling or downstream effector cytokines. Corresponding recombinant proteins can be deployed for supplementary in-vitro mechanistic validation. Nasal and pulmonary tissues are processed for immunohistochemistry to characterize eosinophil infiltration and alarmin expression. This integrated pipeline spans modelling, behavioural assessment, serology, histopathology and mechanistic analysis under consistent quality standards. It supports high-throughput compound screening as well as in-depth “one-airway” nose-lung crosstalk research. Cloud-Clone-generated reagents and services are cited across multiple international peer-reviewed journals; related references are publicly accessible on the corporate website.

Seasonal sneezing episodes represent visible outputs of dysregulated type-2 immunity. Decoding these complex immune events demands coordinated tools covering biomarker quantification, functional protein resources and disease-recapitulating animal models. Cloud-Clone’s full-stack portfolio empowers investigators studying allergic rhinitis, asthma and other airway inflammatory diseases, accelerating the translation of laboratory discoveries toward new therapeutic options to improve patients’ respiratory quality of life.

SuKi Duan
CLOUD-CLONE CORP.WUHAN
Visit us on social media:
LinkedIn
Instagram
TikTok
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

UK Business Reporter

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.